[Individualized use of levosimendan in cardiac surgery].

CONCLUSION: The presented concept of pharmacological preconditioning with 1.25 mg levosimendan followed by individualized additional dosing in cardiac surgery patients with preoperative LVEF ≤40% suggests that this concept is safe, with possible advantages regarding the need of inotropic agents, renal replacement therapy, and 30-day mortality, compared to the current literature. Individualized treatment with levosimendan to support hemodynamics and a timely reduction of inotropic agents needs further confirmation in randomized trials.
PMID: 33001236 [PubMed - as supplied by publisher]

Source: Der Anaesthesist - September 30, 2020 Category: Anesthesiology Authors: Woehrle T, Mehringer L, Juchem G, Dashkevich A, Weis M, Schünemann M, Kilger E Tags: Anaesthesist Source Type: research